Studie - Hypoparathyroidism – Pipeline Review, H1 2012

Hypoparathyroidism — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Hypoparathyroidism - Pipeline Review, H1 2012', provides an overview of the Hypoparathyroidism therapeutic pipeline. This report provides information on the therapeutic development for Hypoparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypoparathyroidism. 'Hypoparathyroidism - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Hypoparathyroidism.
- A review of the Hypoparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypoparathyroidism pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hypoparathyroidism.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypoparathyroidism pipeline depth and focus of Hypoparathyroidism therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hypoparathyroidism Overview 6

Therapeutics Development 7

An Overview of Pipeline Products for Hypoparathyroidism 7

Hypoparathyroidism Therapeutics under Development by Companies 9

Hypoparathyroidism Therapeutics under Investigation by Universities/Institutes 10

Late Stage Products 11

Comparative Analysis 11

Mid Clinical Stage Products 12

Comparative Analysis 12

Hypoparathyroidism Therapeutics — Products under Development by Companies 13

Hypoparathyroidism Therapeutics — Products under Investigation by Universities/Institutes 14

Companies Involved in Hypoparathyroidism Therapeutics Development 15

NPS Pharmaceuticals, Inc. 15

Hypoparathyroidism — Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Drug Profiles 21

Human Parathyroid Hormone 1-34 - Drug Profile 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Natpara - Drug Profile 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

PTH 1-34 - Drug Profile 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Parathyroid Hormone - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Forteo - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

PTH (1-84) - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Hypoparathyroidism Therapeutics — Drug Profile Updates 29

Hypoparathyroidism — Product Development Milestones 30

Featured News & Press Releases 30

Nov 07, 2011: NPS Pharmaceuticals Announces Positive Top-Line Results From Pivotal Phase III REPLACE Study Of NPSP558 In Hypoparathyroidism 30

Sep 16, 2011: NPS Pharmaceuticals Highlights Hypoparathyroidism Data To Be Presented At Annual Meeting Of American Society For Bone And Mineral Research 31

Mar 01, 2011: NPS Pharmaceuticals Completes Patient Randomization In Phase III REPLACE Study Of NPSP558 In Hypoparathyroidism 32

Dec 22, 2008: NPS Pharmaceuticals Initiates Phase III 'REPLACE' Study Of NPSP558 In Hypoparathyroidism 33

Sep 15, 2008: Positive Interim Data From Phase II Study Of NPSP558 (Parathyroid Hormone 1-84) For Hypoparathyroidism Reported At ASBMR Annual Meeting 33

May 03, 2005: Abbott presents promising Zemplar (paricalcitol) capsules phase III data showing potential for earlier treatment of kidney disease complication 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 36

Disclaimer 36





List of Tables

Number of Products Under Development for Hypoparathyroidism, H1 2012 7

Products under Development for Hypoparathyroidism — Comparative Analysis, H1 2012 8

Number of Products under Development by Companies, H1 2012 9

Number of Products under Investigation by Universities/Institutes, H1 2012 10

Comparative Analysis by Late Stage Development, H1 2012 11

Comparative Analysis by Mid Clinical Stage Development, H1 2012 12

Products under Development by Companies, H1 2012 13

Products under Investigation by Universities/Institutes, H1 2012 14

NPS Pharmaceuticals, Inc., H1 2012 15

Assessment by Monotherapy Products, H1 2012 16

Assessment by Stage and Route of Administration, H1 2012 18

Assessment by Stage and Molecule Type, H1 2012 20

Hypoparathyroidism Therapeutics — Drug Profile Updates 29





List of Figures

Number of Products under Development for Hypoparathyroidism, H1 2012 7

Products under Development for Hypoparathyroidism — Comparative Analysis, H1 2012 8

Products under Development by Companies, H1 2012 9

Products under Investigation by Universities/Institutes, H1 2012 10

Late Stage Products, H1 2012 11

Mid Clinical Stage Products, H1 2012 12

Assessment by Monotherapy Products, H1 2012 16

Assessment by Route of Administration, H1 2012 17

Assessment by Stage and Route of Administration, H1 2012 18

Assessment by Molecule Type, H1 2012 19

Assessment by Stage and Molecule Type, H1 2012 20

• Growth Hormone Deficiency – Pipeline Review, H1 2013
• Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013
• Growth Disorders – Pipeline Review, H1 2013
• Kidney Fibrosis – Pipeline Review, H1 2013
• Urinary Incontinence – Pipeline Review, H1 2013
• Global Endocrinology Drugs Market 2012-2016
• Inguinal Hernia Global Clinical Trials Review, H1, 2013
• End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline Review, H2 2012
• Microalbuminuria – Pipeline Review, H2 2012
• Nocturia – Pipeline Review, H2 2012
• Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012
• Hypoparathyroidism – Pipeline Review, H2 2012
• Proteinuria – Pipeline Review, H2 2012
• Thyroid Gland Disorders – Pipeline Review, H2 2012
• Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H2 2012
• Hypothyroidism Global Clinical Trials Review, H2, 2012
• Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2012
• Other Genito Urinary Disorders – Pipeline Review, H2 2012
• Urinary Retention Global Clinical Trials Review, H2, 2012
• Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Review, H2 2012